Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges [Yahoo! Finance]
Structure Therapeutics Inc. (GPCR)
Company Research
Source: Yahoo! Finance
What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing dated February 17, 2026, that it initiated a new position in Structure Therapeutics (NASDAQ:GPCR) by purchasing 90,000 shares. The quarter-end value of the stake stood at $6.26 million, reflecting pricing as of December 31, 2025. What else to know This new position made up 4.62% of B Group's reportable U.S. equity assets as of the December 31, 2025, filing. Top holdings after the filing: NASDAQ:ADMA: $44.83 million (33.2% of AUM) NASDAQ:CLLS: $15.88 million (11.8% of AUM) NASDAQ:PALI: $10.57 million (7.8% of AUM) NASDAQ:TSHA: $9.90 million (7.3% of AUM) NASDAQ:PRAX: $9.80 million (7.3% of AUM) As of Friday, GPCR shares were priced at $48.59, up a staggering 132% over the past year and well outperforming the S&P 500, which is instead up about 15% in the same period. Company overview Metric Value Price (as of Friday) Market Capitalization $3.4 billion Net Income (TTM)
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics (GPCR) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
- Structure Therapeutics CEO on the company's oral GLP-1 opportunity [CNBC]CNBC
- Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics (GPCR) was given a new $145.00 price target by BMO Capital Markets. They now have an "outperform" rating on the stock.MarketBeat
- Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target [Seeking Alpha]Seeking Alpha
GPCR
Sec Filings
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- 3/23/26 - Form 4
- GPCR's page on the SEC website